影响转移性结直肠癌（mCRC）化疗方案选择的因素。
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).
作者信息
Rossi Luigi, Vakiarou Foteini, Zoratto Federica, Bianchi Loredana, Papa Anselmo, Basso Enrico, Verrico Monica, Lo Russo Giuseppe, Evangelista Salvatore, Rinaldi Guilia, Perrone-Congedi Francesca, Spinelli Gian Paolo, Stati Valeria, Caruso Davide, Prete Alessandra, Tomao Silverio
机构信息
Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Rome, Italy; Oncology Unit, ICOT, Latina, Italy.
出版信息
Cancer Manag Res. 2013 Nov 19;5:377-85. doi: 10.2147/CMAR.S47986.
Abstract
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor biology, and patient clinical characteristics, will be one that can maintain quality of life and long-term survival, and even cure selected patients. This review is an overview of the different therapeutic approaches available in metastatic colorectal cancer, for the purpose of defining personalized therapeutic algorithms according to tumor biology and patient clinical features.
摘要
转移性结直肠癌的管理需要多模式方法，并且必须由经验丰富的多学科专家团队来实施。根据疾病的定位和范围、肿瘤生物学特性以及患者的临床特征，选择最佳的个体化治疗方式，应是能够维持生活质量和长期生存，甚至治愈部分患者的方法。本综述概述了转移性结直肠癌可用的不同治疗方法，目的是根据肿瘤生物学特性和患者临床特征确定个性化治疗方案。
相似文献
1
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).影响转移性结直肠癌（mCRC）化疗方案选择的因素。
Cancer Manag Res. 2013 Nov 19;5:377-85. doi: 10.2147/CMAR.S47986.
2
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).转移性结直肠癌（mCRC）：法国肿瘤学会临床实践指南，用于诊断、治疗和随访（SNFGE、FFCD、GERCOR、UNICANCER、SFCD、SFED、SFRO、SFR）。
Dig Liver Dis. 2019 Oct;51(10):1357-1363. doi: 10.1016/j.dld.2019.05.035. Epub 2019 Jul 15.
3
Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes-The University College London Hospital (UCLH) Experience.转移性结直肠癌（mCRC）的多模式治疗可改善预后——伦敦大学学院医院（UCLH）的经验
Cancers (Basel). 2020 Nov 27;12(12):3545. doi: 10.3390/cancers12123545.
4
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.ESMO 结肠癌和直肠癌患者管理共识指南。 个体化临床决策方法。
Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.
5
The changing face of treatment for metastatic colorectal cancer.转移性结直肠癌治疗的变化。
Expert Rev Anticancer Ther. 2019 Jan;19(1):61-70. doi: 10.1080/14737140.2019.1543593. Epub 2018 Nov 9.
6
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
7
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy.在一名接受含阿柏西普一线化疗的老年结直肠癌患者中，药物基因组学与多学科管理的相关性
Front Oncol. 2020 Aug 4;10:1155. doi: 10.3389/fonc.2020.01155. eCollection 2020.
8
Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.多器官转移性结直肠癌患者一线姑息性联合化疗中进行额外肿瘤减瘤术的安全性和可行性。
Oncologist. 2020 Aug;25(8):e1195-e1201. doi: 10.1634/theoncologist.2019-0693. Epub 2020 Jun 16.
9
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.转移性结直肠癌患者仅接受化疗即可获得持久的完全缓解。
Clin Colorectal Cancer. 2011 Sep;10(3):178-82. doi: 10.1016/j.clcc.2011.03.023. Epub 2011 Apr 24.
10
Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.转移性结直肠癌管理的新型质量指标揭示了澳大利亚各治疗中心在这些指标上存在显著差异。
Asia Pac J Clin Oncol. 2015 Sep;11(3):262-71. doi: 10.1111/ajco.12355. Epub 2015 Apr 14.
引用本文的文献
1
Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases.结直肠癌肝转移不同治疗方式的预后因素及治疗效果
World J Gastrointest Oncol. 2020 Oct 15;12(10):1177-1194. doi: 10.4251/wjgo.v12.i10.1177.
2
and Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.并发性结直肠癌标准化学疗法反应的预后和预测生物标志物：单机构研究。
Cells. 2020 Jan 15;9(1):219. doi: 10.3390/cells9010219.
3
Glutathione S-transferase M1 null genotype related to poor prognosis of colorectal cancer.谷胱甘肽S-转移酶M1缺失基因型与结直肠癌预后不良相关。
Tumour Biol. 2016 Aug;37(8):10229-34. doi: 10.1007/s13277-015-4676-4. Epub 2016 Jan 30.
4
A retrospective review of cancer treatments and outcomes among Inuit referred from Nunavut, Canada.对从加拿大努纳武特地区转诊的因纽特人中癌症治疗及治疗结果的回顾性研究。
Curr Oncol. 2015 Aug;22(4):246-51. doi: 10.3747/co.22.2421.
5
Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.与先进行原发性肿瘤切除然后对不可切除的同步转移结直肠癌进行化疗相比， upfront全身化疗是一种可行的选择。 （注：“upfront”在这里可理解为“ upfront”，有“在开始时、预先”等意思 ）
World J Surg Oncol. 2015 Apr 24;13:162. doi: 10.1186/s12957-015-0570-1.
本文引用的文献
1
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.regorafenib 单药治疗既往治疗的转移性结直肠癌（CORRECT）：一项国际、多中心、随机、安慰剂对照、3 期临床试验。
Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
2
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.贝伐珠单抗治疗转移性结直肠癌（ML18147）一线进展后的延续治疗：一项随机 3 期临床试验
Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.
3
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.ESMO 结肠癌和直肠癌患者管理共识指南。 个体化临床决策方法。
Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.
4
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.在既往接受基于奥沙利铂方案治疗的转移性结直肠癌患者中，阿柏西普联合氟尿嘧啶、亚叶酸钙和伊立替康可改善生存，这在一项 III 期随机试验中得到证实。
J Clin Oncol. 2012 Oct 1;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4.
5
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.在转移性结直肠癌一线治疗中，西妥昔单抗联合连续或间断氟尿嘧啶、亚叶酸钙和奥沙利铂（北欧 FLOX）与 FLOX 单药治疗的 III 期临床试验：NORDIC-VII 研究。
J Clin Oncol. 2012 May 20;30(15):1755-62. doi: 10.1200/JCO.2011.38.0915. Epub 2012 Apr 2.
6
Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials.系统化疗在结直肠肝转移灶切除或可切除治疗中的作用：随机对照试验的系统评价和荟萃分析。
Oncol Rep. 2012 Jun;27(6):1849-56. doi: 10.3892/or.2012.1740. Epub 2012 Mar 22.
7
Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.抗 EGFR 药物治疗 KRAS 野生型结直肠癌肝转移局限性患者的可切除性和疗效：一项荟萃分析。
Int J Colorectal Dis. 2012 Aug;27(8):997-1004. doi: 10.1007/s00384-012-1438-2. Epub 2012 Feb 23.
8
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.XELOX 联合贝伐珠单抗一线治疗后，XELOX 联合贝伐珠单抗或贝伐珠单抗单药维持治疗转移性结直肠癌患者：III 期 MACRO TTD 研究。
Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10.
9
Optimal management of pulmonary metastases from colorectal cancer.结直肠癌肺转移的最佳处理策略。
Expert Rev Anticancer Ther. 2011 Oct;11(10):1567-75. doi: 10.1586/era.11.123.
10
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.西妥昔单抗联合奥沙利铂一线治疗晚期结直肠癌的随机 3 期 MRC COIN 试验结果。
Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.
Zotero 插件